While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the low-to-mid hundreds, all the way up to over $1,000 per share. At those steep prices, it’s pretty hard to get any decent share count leverage.

Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.

Every week we screen our 24/7 Wall St. research database looking for stocks covered by top Wall Street analysts that are trading under the $10 level and could provide investors with some solid upside potential. While these stocks are much more suited for aggressive accounts, they could prove to be exciting additions to portfolios in need of solid alpha potential.

New Age Beverages

The marijuana industry is getting plenty of attention, and this company is as well. New Age Beverages Corp. (NASDAQ: NBEV) engages in the development, marketing, sales and distribution of Ready-to-Drink beverages. Its brand includes Coco Libre, Xing Tea, Xing Energy, Aspen Pure, Bucha Live Kombucha, Mellow Mood and One Drop.

At the end of 2018, the company launched its Noni+Collagen product and announced that, within its first two months of sales, it generated over $4 million in revenue in initial test markets. The product was created by the company’s Morinda division and currently offers the product in 50-milliliter glass bottle shots, positioned as a once-daily use, sold in three 10 packs for a 30-day supply. In addition to this new product, New Age announced in January an agreement to sell Marley branded cannabis-infused beverages.

Alliance Global has a Buy rating and an $8 price target on the shares. The consensus target price across Wall Street is even higher at $8.85, and the shares closed trading on Friday at $4.78.

Northern Oil and Gas

SunTrust analysts are very positive on this small-cap energy play. Northern Oil and Gas Inc. (NYSE: NOG) is engaged in the acquisition, exploration, development and production of oil and natural gas properties, primarily in the Bakken and Three Forks formations within the Williston Basin in North Dakota and Montana.

SunTrust pointed out in a recent report that Northern Oil and Gas is the largest non-operator in the Williston Basin. With Bakken returns continuing to improve to well above 50% and the company’s operating partners representing what many see as the best operators in the basin, and the analyst sees upside potential to current estimates.

Despite the greater difficulty in forecasting production owing to the non-operated business model, SunTrust anticipates that Northern Oil and Gas should benefit from record well results from operating partners and strong Bakken differentials.

After Northern Oil and Gas posted solid results recently, the SunTrust analysts raised its price target to $5 from $4, which compares to a $4.06 consensus target. The stock was trading at $2.68 on Friday’s close.

Ranger Energy Services

This small-cap oilfield service play also has big upside potential. Ranger Energy Services Inc. (NYSE: RNGR) engages in the provision of service rigs and associated services. It operates through three segments: The High Specification Rig segment provides service rigs and complementary equipment and services.

The Completion and Other Services segment consists of wireline and snubbing lines of business. The Processing Solutions segment is involved in rental, installation, commissioning, start-up, operation and maintenance of mechanical refrigeration units, natural gas liquid (NGL) stabilizer units, NGL storage units and related equipment.

Wells Fargo’s Buy rating comes with an $11 price objective, not far off the consensus target of $10.50. The shares ended the week trading at $8.39.

Recro Pharma

This stock was pounded recently and offers a great entry point. Recro Pharma Inc. (NASDAQ: REPH) is a pharmaceutical company that engages in the research and development of non-opioid therapeutics for the treatment of acute postoperative pain.

Its Acute Care segment focuses on developing innovative products for hospital and related settings. The Contract Development and Manufacturing segment leverages the company’s formulation expertise to develop and manufacture pharmaceutical products using the company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine and Fadolmidine.

Oppenheimer has an Outperform rating with a $15 price target. The posted consensus target is $8.70, and the shares closed trading at $8.51 on Friday.

TG Therapeutics

Takeover chatter on this company has been around for some time now. TG Therapeutics Inc. (NASDAQ: TGTX) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases.

Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics also is developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor.

The Buy rating at Cantor Fitzgerald comes with a giant $17 price target, though the consensus target is slightly higher at $17.71. The stock most recently traded at $8.47 per share.

Get Our Free Investment Newsletter

I have read, and agree to the Terms of Use

These are five more stocks for very aggressive accounts looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms do have research coverage.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.